# Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

> **NCT00118040** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Recurrent Bladder Carcinoma
- Stage I Bladder Cancer AJCC v6 and v7
- Stage II Bladder Cancer AJCC v6 and v7
- Stage III Bladder Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Genistein
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Placebo Administration
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT00118040
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-24
- **Primary completion:** 2010-08-15
- **Final completion:** 2010-08-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118040, "Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00118040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*